2020 cohort company Astarte recently wrote a guest article for Healthcare IT Today about how tech can optimize protocol-driven care for children with medical complexity. Read more here.
2021 cohort company Genesis has landed its second key clearance from the U.S. Food and Drug Administration — its next step in pursuing full market authorization as part of its goal to better treat millions of cardiac patients. Read more here.
2022 cohort company Mediwhale closed a Series A funding round of $9 million with investors from the United States and South Korea. Read more here.
2020 cohort company Zeto plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials. Read more here.
2020 cohort company Zeto is the recipient of the "Best New Technology Solution for Neurology" award in the 7th annual Awards program conducted by MedTech Breakthrough. Congratulations! Read more here.
2020 cohort company Astarte’s cofounder Tammi Jantzen wrote an article for HIT Consultant about unleashing the power of protocols in critical care. Read more here.
2019 cohort company OMNY Health and Datavant have announced a collaboration agreement to accelerate the delivery of de-identified, real-world data (RWD) from provider organizations to clinical researchers and drug developers. Read more here.
2022 cohort company Mediwhale is the winner of the CKD Challenge, a competition to find innovative technological solutions to reduce the burden of chronic kidney disease (CKD), a severe, progressive, and unknown disease that affects 15% of the Spanish population. Read more here.